Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 13, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
On March 12, 2007, the GlaxoSmithKline Employee Trust ("the GSK Trust") executed the following transactions on behalf of employee incentive plans:
- Transferred 19,933 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Sold 11,326 ADRs on behalf of participants in the SmithKline Beecham Mid-Term Incentive Plan at a price of $55.49 per ADR.
- Transferred 19,988 ADRs to participants in the SmithKline Beecham Mid-Term Incentive Plan.
The GSK Trust is a discretionary trust for current and former employees. Three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the trust shares in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total volume of shares and ADRs transferred or sold by the GSK Trust on March 12, 2007.
- Confirm the sale price of $55.49 per ADR for the Mid-Term Incentive Plan transactions.
- Review the specific employee plans (1991 Option Plan and Mid-Term Incentive Plan) involved in these distributions.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial metrics.